Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06260709 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
A Phase 2 study of Transthyretin Amyloid Cardiomyopathy (ATTR CM), sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT06260709 is a Phase 2 study of Transthyretin Amyloid Cardiomyopathy (ATTR CM) that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 80 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT06260709, a Phase 2 study of Transthyretin Amyloid Cardiomyopathy (ATTR CM), is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for up to 157 weeks (36 months/3 years).
Conditions Studied
Interventions
- DRUG NNC6019-0001
Study Locations (20)
Other
- II. interni klinika VFN - Kardiologie a angiologie - Prague
- Ap-Hp-Hopital Henri Mondor - Créteil
- Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1 - Toulouse
- UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie - Heidelberg
- Universitätsklinik Heidelberg Innere Medizin III Kardiologie, Angiologie, Pneumologie - Heidelberg
- LMU Klinikum München Klinik und Poliklinik 1 - München
- Uniklinik Münster, Klinik für Kardiologie I - Münster
- Universitätsklinikum Münster - Klinik für Kardiologie I - Münster
- Universitatsklinikum Wurzburg AöR - Würzburg
- Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz - Würzburg
California
- Cedars-Sinai Medical Center_Los Angeles - Los Angeles
- Stanford Hlth Cre-Boswell Clin - Stanford
Illinois
- NW Univ-Bluhm Cardiovasc Inst - Chicago
- NW Univ-Bluhm Cardiovasc Inst - Evanston
Arizona
- Mayo Clinic Arizona - Phoenix
Florida
- Mayo Clinic Jacksonville - Jacksonville
Maryland
- Univ of MD Schl of Med - Baltimore
Minnesota
- Mayo Clinic Rochester - Rochester
Alberta
- University of Calgary_Cardiology - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2028-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06260709
The ClinicalTrials.gov registry entry for NCT06260709 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transthyretin Amyloid Cardiomyopathy (ATTR CM) appearing as the primary indexed condition, and to 1 intervention - of which NNC6019-0001 is the first listed.
NCT06260709 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06260709 about?
NCT06260709 is a clinical study titled "A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis". This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "...
What is the current status of trial NCT06260709?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-02-20. Estimated completion is 2028-08-15.
What conditions does trial NCT06260709 study?
This clinical trial studies the following conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM).
What interventions are being tested in trial NCT06260709?
The interventions under investigation include: NNC6019-0001 (DRUG).
Who is sponsoring clinical trial NCT06260709?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06260709 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.